Cantargia reports positive preclinical efficacy data for CAN10 demonstrating anti-fibrotic and anti-inflammatory effects in systemic sclerosis
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced new preclinical data on its anti-inflammatory IL1RAP-binding antibody CAN10 showing that CAN10 reduced established fibrosis in the skin and lungs in an advanced model of systemic sclerosis, a life-threatening autoimmune disorder. CAN10 also normalized biological markers of inflammation and fibrosis, associated with the human disease. The data will be presented in a poster session at the 7[th] Systemic Sclerosis World Congress on 10-12 March, 2022.“These new data strongly support development of CAN10 for treatment of systemic